Amerise Biosciences Limited convened a Board of Directors meeting on Tuesday, May 5, 2026, to approve the audited standalone financial results for the year ended March 31, 2026. The meeting, held at Ahmedabad, commenced at 04:45 PM and concluded at 05:15 PM. The statutory auditor, Bipin & Co., Chartered Accountants, issued an audit report with an unmodified opinion on the financial results for the financial year ended March 31, 2026. The results were submitted to BSE Limited pursuant to Regulation 33 read with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Overview

The company's revenue from operations for FY26 stood at Rs. 25.52 lacs, entirely comprising other operating revenue, compared to Rs. 18.80 lacs in FY25. Total income for FY26 was Rs. 25.52 lacs versus Rs. 18.80 lacs in the prior year. Total expenses for FY26 were Rs. 23.46 lacs against Rs. 18.04 lacs in FY25, driven primarily by other expenses of Rs. 16.09 lacs and employee benefit expenses of Rs. 7.37 lacs. The company recorded a profit before tax of Rs. 2.06 lacs for FY26, compared to Rs. 0.76 lacs in FY25. After accounting for tax expense of Rs. 0.45 lacs (FY25: Rs. 0.19 lacs), net profit after tax for FY26 stood at Rs. 1.61 lacs, up from Rs. 0.57 lacs in FY25.

The following table summarises the key income statement metrics:

Quarterly Performance

For the quarter ended March 31, 2026, the company reported revenue from operations of Rs. 7.92 lacs and total expenses of Rs. 1.79 lacs, resulting in a net profit of Rs. 6.13 lacs. This compares to revenue from operations of Rs. 18.80 lacs and net profit of Rs. 10.59 lacs in the corresponding quarter ended March 31, 2025. For the quarter ended December 31, 2025, revenue from operations was Rs. 4.49 lacs and net profit was Rs. 0.97 lacs.

Balance Sheet Highlights

The company's total assets as at March 31, 2026 stood at Rs. 742.19 lacs, compared to Rs. 846.33 lacs as at March 31, 2025. Non-current assets declined to Rs. 681.00 lacs from Rs. 843.64 lacs, primarily reflecting a decrease in non-current loans from Rs. 605.54 lacs to Rs. 304.03 lacs, partially offset by an increase in investments from Rs. 238.10 lacs to Rs. 376.97 lacs. Current assets increased significantly to Rs. 61.19 lacs from Rs. 2.69 lacs, driven by a rise in bank balances to Rs. 57.42 lacs from Rs. 1.08 lacs.

Cash Flow Summary

The standalone statement of cash flows, prepared under the indirect method as per Ind AS-7, reflects a net decrease in cash from operating activities of Rs. 105.67 lacs for FY26 (FY25: net inflow of Rs. 307.08 lacs), primarily due to a decrease in current liabilities of Rs. 105.75 lacs. Net cash inflow from investing activities was Rs. 162.64 lacs (FY25: outflow of Rs. 306.97 lacs), driven by proceeds from long-term loans and advances of Rs. 301.51 lacs, partially offset by investments in shares of Rs. 138.87 lacs. There were no cash flows from financing activities in either period. The net increase in cash and cash equivalents for FY26 was Rs. 56.97 lacs, resulting in a closing balance of Rs. 59.19 lacs compared to Rs. 2.22 lacs at the start of the year.

Earnings Per Share and Other Details

The paid-up equity share capital of the company remained unchanged at Rs. 660.69 lacs (face value of Rs. 1/- each) as at March 31, 2026. Basic and diluted earnings per share (not annualised) for the full year FY26 were Rs. 0.00 each. The company operates in a single business segment, and accordingly no separate segment results have been disclosed. The financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 5, 2026, at Ahmedabad.

Amerise biosciences Limited has announced key changes in its management structure, with the resignation and appointment of Company Secretary & Compliance Officer positions taking effect simultaneously on April 15, 2026. The company has informed BSE Limited about these changes in compliance with SEBI regulations.

Management Transition Details

The company has experienced a complete transition in its Company Secretary role, with both resignation and appointment occurring on the same date to ensure operational continuity.

Resignation of Ms. Minal Lakhani

Ms. Minal Lakhani has tendered her resignation from the position of Company Secretary & Compliance Officer due to personal reasons. Her resignation has been accepted by the company, and she will be relieved from all duties and responsibilities effective April 15, 2026. In her resignation letter dated April 14, 2026, Ms. Lakhani confirmed her commitment to extend full cooperation for smooth transition and proper handover of statutory records and documents as required under applicable laws.

Appointment of Ms. Soni Pandiya

Ms. Soni Pandiya has been appointed as the new Company Secretary & Compliance Officer under Regulation 6(1) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. She brings significant expertise to the role with her professional qualifications and experience.

Regulatory Compliance

The company has made these disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Part A of Schedule III to the Listing Regulations. All required documentation and annexures have been submitted to BSE Limited as per SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015. The notification was signed by Albert Hines, Wholetime Director of the company, ensuring proper authorization of the management changes.